CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sterling Biotech Limited (in Liquidation) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sterling Biotech Limited (in Liquidation)
Sandesara Estate, Atladara- Padra Road
Phone: +91 2652321720p:+91 2652321720 VADODARA, 390012  India Fax: +91 2652680257f:+91 2652680257
Filed for Bankruptcy on 5/8/2019
On 6/11/2018, the National Company Law Tribunal (NCLT) initiated a Corporate Insolvency Resolution Process for Sterling Biotech Limited pursuant to an Insolvency Petition filed against the Company by Andhra Bank.
On 5/8/2019, the NCLT ordered Sterling Biotech Limited Liquidated. Dr. Mamta Binani was appointed as the Liquidator of Sterling Biotech Limited.
In November of 2022, Sterling Biotech Limited's assets were acquired by Perfect Day, Inc.
This company is no longer actively traded on any major stock exchange.
Business Summary
Sterling Biotech Limited is engaged in the manufacturing of pharma-grade gelatin and di-calcium phosphate and other pharma products. The Company manufactures gelatin from animal bones. It also manufactures gelatine and its derivatives, resinoids, glues, and allopathic pharmaceutical preparations. It offers anticancer products, such as DOXO Rubicin, which is an anti-cancer chemotherapy drug and is classified as an anthracycline antibiotic; IDARUBICIN, which is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug; Daunorubicinis, which is used to treat acute lymphocytic and myelocyticleukemias; IMATINIB, which is a drug used to treat certain cancers, and EPI Rubicin, which is an anthracycline drug used for chemotherapy. Its other products include Lovastatin, which is a cholesterol-lowering agent; DACARBAZINE, which is used to treat Hodgkin disease and malignant melanoma, and Simvastatin, which is a lipid-lowering drug used to decrease heart problems in those at a high risk.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20173/31/2017Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Chief Executive Officer, Managing Director Nitin J.Sandesara
Joint Managing Director, Executive Director Chetan J.Sandesara 7/15/2008 7/15/2008
Independent Director MayuriPatel 3/25/2015 3/25/2015
3 additional Officers and Directors records available in full report.

Business Names
Business Name
512299
STERLINBIO
Sterling International Enterprises Ltd

General Information
Number of Employees: 1,354 (As of 12/31/2013)
Outstanding Shares: 272,170,388 (As of 3/31/2017)
Shareholders: 33,802
Stock Exchange: NSE
Fax Number: +91 2652680257


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023